XENE Xenon Pharmaceuticals Inc.

8-K Current Report

Filed: March 12, 2026

Health Care

Pharmaceutical Preparations

Xenon Pharmaceuticals Inc. (XENE) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 8.01: Other Events
Item 1.01: Entry into a Material Definitive Agreement

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Xenon raised ~$707.7M net proceeds via public offering of 12,236,843 shares + 877,194 pre-funded warrants at $57.00/share
• Underwriters exercised full 30-day overallotment option (1,710,526 additional shares) same day as pricing — strong demand signal

+3 more insights

Item 8.01 · Other Events

• Filing references a pre-funded warrant offering — typically used when investors near ownership thresholds, suggesting large institutional buyer(s)
• Text fragment indicates details of offering terms are described elsewhere in the filing — investors should review full 8-K for pricing and size

Other Xenon Pharmaceuticals Inc. 8-K Filings

Get deeper insights on Xenon Pharmaceuticals Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.